Cardiovascular Medicine 2025 Wrapped: The Big Picture

Drs Harrington and Gibson's annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ever lower LDL-C with drugs or even gene editing are among the highlights.

This podcast is intended for healthcare professionals only.

To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington

New ACS Guidelines

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes

https://doi.org/10.1161/CIR.0000000000001309

ACS Guideline Chair and Vice-Chair Discussion

https://www.medscape.com/viewarticle/acs-guidelines-2025-key-points-chair-and-vice-chair-2025a100093l

Antiplatelet/Antithrombotic Strategies

Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI

https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt

Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET)

https://www.nejm.org/doi/full/10.1056/NEJMoa2507980

Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC)

https://www.nejm.org/doi/full/10.1056/NEJMoa2507532

Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making : ENGAGE AF-TIMI 48 Trial Analysis

https://doi.org/10.1016/j.jacadv.2025.102504

Factor XI Inhibitors

Bristol Myers, J&J Stop Blood Clotting Drug Trial After Interim Review

https://www.medscape.com/s/viewarticle/bristol-myers-j-j-stop-blood-clotting-drug-trial-after-2025a1000vqu

Bayer's Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention https://www.bayer.com/en/us/news-stories/oceanic-stroke

OAC-Naive Subgroup From OCEANIC-AF Published

https://www.medscape.com/viewarticle/novel-blood-thinner-shows-promise-atrial-fibrillation-2025a10008lz

GLP-1 and Myotrophic Drugs

Lilly's Next-gen Drug Shows Greater Weight Loss Than Zepbound in Late-stage Trial (TRIUMPH-4)

https://www.medscape.com/s/viewarticle/lillys-next-gen-drug-tops-zepbound-weight-loss-late-stage-2025a1000ys1

Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial

https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf

CRISPR and Lipid Lowering

Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease

https://www.nejm.org/doi/full/10.1056/NEJMoa2504747

Gene Therapy Shows Lipid Improvement but Raises Flags

https://www.medscape.com/viewarticle/gene-therapy-shows-lipid-improvement-raises-flags-2025a1000uzw

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3

https://www.nejm.org/doi/full/10.1056/NEJMoa2511778

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke (VESALIUS-CV)

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2514428

Prehospital GLP IIb/IIIa

Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction (CELEBRATE) https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268

You may also like:

Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology

https://www.medscape.com/twic

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.